News

Equity Insider: As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- ...
Healio15d
Q&A: Research is ‘rapidly evolving’ on endocrine-disrupting chemicals and thyroid health
In this Healio Video Exclusive, Caroline T. Nguyen, MD, speaks with Elizabeth N. Pearce, MD, MSc, about how endocrine-disrupting chemicals impact thyroid health. People are exposed to many types of ...
Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy
For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive ...
Pulmonology Advisor6d
AACE Releases Guidance for Management of Multiple Endocrine Neoplasia Type 1
AACE released clinical guidelines on the diagnosis, management, and surveillance of tumors related to multiple endocrine neoplasia type 1.
Becker's Hospital Review2d
Why 47% of breast cancer patients extend endocrine therapy beyond 5 years
More than 46% of women with stage 1 or 2 breast cancer chose to continue endocrine therapy after five years, a recent study found. The study, published in the Journal of the National Cancer Institute, ...
MedPage Today on MSN9d
Non-Hormonal Drug Reduced Hot Flashes From Endocrine Therapy for Breast Cancer
The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine ...
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
"Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has ...
National Institute for Health and Care Excellence28d
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment
Capivasertib (Truqap, AstraZeneca) is indicated 'in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR ... following recurrence or progression on or after an ...